Open-Label Risperidone Treatment of 6 Children and Adolescents with Autism

Chamberlain RS Herman BH . A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism. Biol Psychiatry 1990;28:773–93.

Purdon SE Lit W Labelle A Jones BDW . Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400–5.

McDougle CJ Holmes JP Bronson MR Anderson GM Volkmar FR Price LH , and others. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685–93.

Demb HB . Risperidone in young children with pervasive developmental disorders and other developmental disabilities. J Child Adolesc Psychopharmacol 1996;6:79–80.

Nicolson R Awad G Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37:372–6.

National Institute of Mental Health: Clinical global impressions. Psychopharmacol Bull 1985;21:839–43.

Barthélemy C Adrien JL Tanguay P Garreau B Fermanian J Roux S , and others. The behavioural summarized evaluation: Validity and reliability of a scale for the assessment of autistic behaviours. J Autism Dev Disord 1990;20:189–203.

Doll EA . Vineland social maturity scale. Rev ed. Princeton (NJ): Educational Testing Service; 1952.

Chouinard G Ross-Chouinard A Annable L Jones BD . The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.